			New		Description	l	_				
Sponsor	Product	New Abx Class	Non- traditional Product	New Target		CDC	wно	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I
chaogen	Next- Generation AG				Next-gen AG with extended Gram-negative coverage (Pseudomonas)	1	1		Gram-neg activity including Pseudomonas		
microbe	Amicidin-β		1		Next-generation local antimicrobial	1	1			Broad spectrum	
ntabio	PEI		1	1	Pseudomonas elastase inhibitor	1	1		P. aeruginosa		
ugworks Research	GYROX	1			Gyrase- topoisomerase inhibitor	1	1		Gram-negative activi	ty	
dara Therapeutics	CD201		1	1	Bifunctional immunotherapy	1	1	Acinetobacter+P. aeruginosa + Enterobacteriaceae			
ontraFect	Gram-negative lysins		1	1	Recombinant lysin protein	1	1	P. aeruginosa			
urza	CZ-02	1		1	Novel class Gram- negative	1	1		Broad Spectrum		
ebiopharm sternational SA	Debio1453	1		1	Narrow-spectrum inhibitors of Fabl	1	1		Neisseria Gonorrhoeae		
ntasis nerapeutics	ETX0282CPDP				Oral Gram-negative combination	1	1			Gram-negative activit	У
ntasis nerapeutics	Non-BL PBPi	1			Non-beta-lactam PBPi	1	1		Gram-negative activity		
orge Therapeutics	FG-LpxC-LUNG	1		1	LpxC inhibitor	1	1		Gram-negative activity		
orge Therapeutics	FG-LpxC-UTI	1		1	LpxC inhibitor	1	1		Gram-negative activity		
lorsia	TopESKAPE	1			Dual-acting topoisomerase inhibitor	1	1		Acinetobacter, Pseudomons, and Enterobacteriaceae		
hhibrx	INBRX-111		1	1	Multi-specific antibody	1	1			P. aeruginosa	
ntegrated ioTherapeutics	IBT-V02		1		Multi-valent toxoid vaccine	1	1			S. aureus	
erum	Sulopenem				Oral and IV penem	1	1				Gram-negative activity
1acrolide	Novel Macrolides				Novel macrolide antibiotics with Gram- negative activity	1	1		Gram-negative activity		
1elinta	Pyrrolocytosine	1		1	Novel class, MDR ESKAPE	1	1		Broad spectrum		
1icrobiotix	T3SS Inhibitor		1	1	Virulence modifier	1	1		P. aeruginosa		
1icuRx	MRX-8				Soft drug polymyxin	1	1			Gram-negative activity	
olyphor	OMPTA POL7306	1		1	Novel class, M DR/XDR ESKAPE	1	1			Gram-negative activity	
ecida nerapeutics	RC-01	1		1	LpxC inhibitor	1	1			Enterobacteriacea e + P. aeruginosa	
tiBac	SCB-102		1		Microbiome	1	1		C.difficile		
eres Therapeutics	SER-155		1		Microbiome - transplant patients	1	1	Broad spectrum activity vs CRE/VRE			
ummit nerapeutics	SMT-571 Series	1		1	Novel class, orally active antibiotic	1	1		Neisseria Gonor	rrhoeae	
etraphase narmaceuticals	TP-6076				Next-generation tetracycline	1	1				Acinetopacter + Enterobacteriace ae
edanta	VE303		1		Microbiome	1				C.dij	fficile
enatoRx	VNRX-PBP	1			β-lactamase resistant PBP inhibitor	1	1	Entero- bacteriacae			
isterra	VIS705		1	1	Antibody-drug conjugate	1	1		P. aeruginosa		

CARB-X Antibacterial Devices and Diagnostic Product Portfolio										
			Description							
Sponsor	Туре	Technology	Feasibilty Demonstration	Optimization and Preparation for Development	Product Development	System Integration and Testing				
Helixbind	Hospital Dx	Automated culture-free pathogen ID			Bloodstream Infections					
Proteus	Rapid POC Dx Optical bacterial imaging			POC Diagnostic						
Specific Diagnostics	Hospital Dx	Colorimetric Sensor Array to detect VOCs			Bloodstream Infections					
Talis	Point of care Dx Pathogen ID; Phenotypic AST			ria gonorrhoeae; Iamydia trachomatis						
T2 Biosystems	Hospital Dx Expanded bacteria and resistance panels for T2Dx		Bloodstream infections							

The above projects are Powered by CARB-X utilizing non-dilutive funding from BARDA, Wellcome Trust, & NIAID. Characterizations of new Abx Class and New Target by CARB-X, following Pew pipeline analysis: http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development. Other characterizations by CARB-X experts and external expert opinion. Abx = traditional small molecule antibiotic. Non-traditional Product = not a traditional small molecule antibiotic.